PRIMARY STUDY

Circulating Endocannabinoid Levels as Potential Biomarkers for Mortality in Hemodialysis Patients

Key Findings:  The authors analyzed data from 436 hemodialysis patients. They discovered that patients with higher serum 2-AG had lower 12-month all-cause mortality risks compared to the group with lower serum 2-AG, leading the authors to hypothesize that circulating endocannabinoid level may be used as a predictor for mortality in this patient population.